The Immunosuppressive Landscape in Tumor Microenvironment

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2024 May 1

PMID 38691319

Authors

Wuyi Liu

Huyue Zhou

Wenjing Lai

Changpeng Hu

Rufu Xu

Peng Gu

Menglin Luo

Rong Zhang

Guobing Li

Affiliations

Soon will be listed here.

Abstract

Recent advances in cancer immunotherapy, especially immune checkpoint inhibitors (ICIs), have revolutionized the clinical outcome of many cancer patients. Despite the fact that impressive progress has been made in recent decades, the response rate remains unsatisfactory, and many patients do not benefit from ICIs. Herein, we summarized advanced studies and the latest insights on immune inhibitory factors in the tumor microenvironment. Our in-depth discussion and updated landscape of tumor immunosuppressive microenvironment may provide new strategies for reversing tumor immune evasion, enhancing the efficacy of ICIs therapy, and ultimately achieving a better clinical outcome.

Citing Articles

Recent advances in the role of high-salt diet in anti- and pro-cancer progression.

Tang S, Xu J, Wan P, Jin S, Zhang Y, Xun L Front Immunol. 2025; 16:1542157.

PMID: 39944693 PMC: 11814453. DOI: 10.3389/fimmu.2025.1542157.

PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1.

Zhu L, Qu Y, Yang J, Shao T, Kuang J, Liu C Front Immunol. 2024; 15:1486888.

PMID: 39687608 PMC: 11646888. DOI: 10.3389/fimmu.2024.1486888.

A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence.

Liu X, Chen H, Tan G, Zhong L, Jiang H, Smith S Front Immunol. 2024; 15():1496627.

PMID: 39669560 PMC: 11634813. DOI: 10.3389/fimmu.2024.1496627.

References

Matsushita H, Vesely M, Koboldt D, Rickert C, Uppaluri R, Magrini V . Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012; 482(7385):400-4. PMC: 3874809. DOI: 10.1038/nature10755. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Kakavand H, Wilmott J, Long G, Scolyer R . Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology. 2016; 48(2):194-202. DOI: 10.1016/j.pathol.2015.12.010. View

Joshi S, Badgwell B . Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021; 71(3):264-279. PMC: 9927927. DOI: 10.3322/caac.21657. View

Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Alsaab H, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw S . PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol. 2017; 8:561. PMC: 5572324. DOI: 10.3389/fphar.2017.00561. View

Wu Y, Chen W, Xu Z, Gu W . PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition. Front Immunol. 2019; 10:2022. PMC: 6718566. DOI: 10.3389/fimmu.2019.02022. View

Berry S, Taube J . Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma. Oncoimmunology. 2015; 4(10):e1029704. PMC: 4589064. DOI: 10.1080/2162402X.2015.1029704. View

10.

Yuan Y, Adam A, Zhao C, Chen H . Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy. Cancers (Basel). 2021; 13(4). PMC: 7915065. DOI: 10.3390/cancers13040663. View

11.

Hargadon K, Johnson C, Williams C . Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018; 62:29-39. DOI: 10.1016/j.intimp.2018.06.001. View

12.

Bagchi S, Yuan R, Engleman E . Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol. 2020; 16:223-249. DOI: 10.1146/annurev-pathol-042020-042741. View

13.

Qian W, Zhao M, Wang R, Li H . Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. J Hematol Oncol. 2021; 14(1):147. PMC: 8444356. DOI: 10.1186/s13045-021-01161-8. View

14.

Wang J, Sanmamed M, Datar I, Tianjiao Su T, Ji L, Sun J . Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell. 2018; 176(1-2):334-347.e12. PMC: 6365968. DOI: 10.1016/j.cell.2018.11.010. View

15.

Maruhashi T, Sugiura D, Okazaki I, Shimizu K, Maeda T, Ikubo J . Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity. 2022; 55(5):912-924.e8. DOI: 10.1016/j.immuni.2022.03.013. View

16.

Hirayasu K, Arase H . Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. J Hum Genet. 2015; 60(11):703-8. DOI: 10.1038/jhg.2015.64. View

17.

Stahl M, Goldberg A . Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets. Curr Oncol Rep. 2019; 21(4):37. DOI: 10.1007/s11912-019-0781-7. View

18.

Deng M, Gui X, Kim J, Xie L, Chen W, Li Z . LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018; 562(7728):605-609. PMC: 6296374. DOI: 10.1038/s41586-018-0615-z. View

19.

Inui M, Sugahara-Tobinai A, Fujii H, Itoh-Nakadai A, Fukuyama H, Kurosaki T . Tolerogenic immunoreceptor ILT3/LILRB4 paradoxically marks pathogenic auto-antibody-producing plasmablasts and plasma cells in non-treated SLE. Int Immunol. 2016; 28(12):597-604. DOI: 10.1093/intimm/dxw044. View

20.

Sugahara-Tobinai A, Inui M, Metoki T, Watanabe Y, Onuma R, Takai T . Augmented ILT3/LILRB4 Expression of Peripheral Blood Antibody Secreting Cells in the Acute Phase of Kawasaki Disease. Pediatr Infect Dis J. 2019; 38(4):431-438. DOI: 10.1097/INF.0000000000002259. View